The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trials

Bill D. Gogas1,2, MD; Christos V. Bourantas1, MD, PhD; Hector M. Garcia-Garcia3, MD, MSc, PhD; Yoshinobu Onuma1, MD; Takashi Muramatsu1, MD, PhD; Vasim Farooq1, MBChB; Roberto Diletti1, MD; Robert-Jan M. van Geuns1, MD, PhD; Bernard De Bruyne4, MD, PhD; Bernard Chevalier5, MD; Leif Thuesen6, MD; Pieter C. Smits7, MD, PhD; Dariusz Dudek8, MD; Jacques Koolen9, MD, PhD; Stefan Windecker10, MD; Robert Whitbourn11, MD; Dougal McClean12, MD; Cecile Dorange13, MS